KSMO ´ë±¸°æºÏ/ºÎ»ê¿ï»ê°æ³²Áöȸ °øµ¿ ½ÉÆ÷Áö¾ö : 2023-12-01
±³À°ÀÏÀÚ : 2023-12-01
±³À°Àå¼Ò : °æÁÖÈúÆ° B1 ü¸®·ë
±³À°ÁÖÁ¦ : KSMO ´ë±¸°æºÏ/ºÎ»ê¿ï»ê°æ³²Áöȸ °øµ¿ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÁ¾¾ç³»°úÇÐȸ ´ë±¸°æºÏÁ¾¾çÁöȸ
´ã´çÀÚ : Â÷¹ÎÁÖ
¿¬¶ôó : 010-3207-9012
À̸ÞÀÏ : minju.cha@ksmo
±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12¿ù 01ÀÏ Ã¼¸®·ë 14:30~14:55 Novel endocrine therapies for HR+/HER2- breast cancer ȲÀ±Èñ(´ë±¸°¡Å縯´ëÇб³º´¿ø)
±³À°½Ã°£ 12¿ù 01ÀÏ Ã¼¸®·ë 14:55~15:20 Lung cancer: recent update in systemic therapy ±èÇý¶ó(°è¸í´ëÇб³ µ¿»êÀÇ·á¿ø)
±³À°½Ã°£ 12¿ù 01ÀÏ Ã¼¸®·ë 15:20~15:45 Chemotherapy induced Hypersensitivity reaction ÃÖÇõÁø(°æºÏÀÇ´ë)
±³À°½Ã°£ 12¿ù 01ÀÏ Ã¼¸®·ë 15:45~16:10 Cancer associated venous thromboembolic disease ÁöÁØÈ£(»ï¼ºÃ¢¿øº´¿ø)
ÈÞ½Ä 12¿ù 01ÀÏ Ã¼¸®·ë 16:10~16:20 Coffee Break ()
±³À°½Ã°£ 12¿ù 01ÀÏ Ã¼¸®·ë 16:20~17:00 The Promising Role of Pembrolizumab : Reinforce therapeutic paradigms in new TNBC era ÀÌÀÎÈñ(Ä¥°î°æºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 12¿ù 01ÀÏ Ã¼¸®·ë 17:00~17:40 Quality-based Biosimilar Development: Onbevzi¢ç Á¤Çö¿±(°í½Å´ëÇб³º´¿ø)
±³À°½Ã°£ 12¿ù 01ÀÏ Ã¼¸®·ë 17:40~18:00 3yr long-term evidence of IO based 1st line aGC treatment for PD-L1 All-comer population ±èÁø¿µ(°è¸í´ëÇб³ µ¿»êÀÇ·á¿ø)
±³À°½Ã°£ 12¿ù 01ÀÏ Ã¼¸®·ë 18:00~18:20 IO/IO regimen, a life-saving and changing treatment in aRCC ÀÓÇö¼ö(¿ï»ê´ëÇб³º´¿ø)